H. Daniel Perez M.D.

H. Daniel Perez, MD has a diverse range of work experience. H. Daniel currently holds the position of Chief Development Officer at IMIDomics Inc. starting in August 2022. In 2014, they founded Naia Pharmaceuticals and served as the President, CEO, and Chairman of the Board. From 2011, they were a part of The J. David Gladstone Institutes as a member of the President's Council. H. Daniel also served on the Board of Directors for Presidio Pharmaceuticals starting in 2007. In 2006, they joined Cardium Pharmaceuticals as a Scientific Advisory Board Member. In 2011, they joined GlaxoSmithKline China's Investment Board until January 2023. H. Daniel has been a member of Vertex Pharmaceuticals' Advisory Board for Neurodegeneration since January 2010, a role they will continue until January 2023. From 2011 to 2015, they served as the Chairman of the Board of Directors for Celtaxsys. From January 2007 to September 2014, they worked as a Venture Partner at Bay City Capital, LLC. Additionally, they held the position of President and CEO at Presidio Pharmaceuticals, Inc. from October 2011 to February 2013.

H. Daniel Perez, MD began their education journey in 1969 by enrolling at the University of Buenos Aires. From 1969 to 1972, they pursued their MD degree in the field of Medicine at the University of Buenos Aires. Additional details about the start and end years of their education are not provided.